Ixchiq HCP

Menu
Menu

AREAS AT RISK FOR CHIKUNGUNYA VIRUS8

Prior to 2025, current or previous autochthonous transmission of the chikungunya virus has been reported from 119 countries and territories.9
  • 263,592 suspected and 181,679 confirmed chikungunya cases and 155 chikungunya-related deaths have been reported globally from January to September 2025.
  • IXCHIQ® is indicated for the prevention of disease caused by the chikungunya virus.  It is not indicated for treating chikungunya or chikungunya related death and sequelae.
Over 75% of the world’s population is estimated to live in areas at risk of chikungunya (according to 2015 estimates).10
Recent outbreaks in Argentina, Paraguay, and Uruguay support predictions that climate change may be expanding the distribution of chikungunya virus. This expansion increases the potential risk of epidemic transmission in highly populated temperate regions such as the United States, China, and continental Europe.11
12-month chikungunya virus disease case notification rate per 100,000 population (February 2025 to January 2026)8
Adapted from the European Centre for Disease Prevention and Control.8
Countries with most cases
Chikungunya in Canada
Chikungunya outbreak
SYMPTOMS
As of mid-July 2025, the countries reporting the highest number of chikungunya cases are:12
  • Brazil (185,553)
  • Bolivia (4,721)
  • Argentina (2,836)
  • Peru (55)
Chikungunya in travellers returning to Canada13
Results from a pilot laboratory-based surveillance study which revealed a marked increase in identified laboratory-based travel-related cases of chikungunya (2024).

LATIN AMERICA AND CARIBBEAN

The Latin America and Caribbean regions were the top travel destinations linked with laboratory-based cases of chikungunya in 2024.13

57

chikungunya laboratory-based travel-related cases were identified in 2024 (N=752).13

>500%

There was a >500% increase in cases vs. 2023.13

Laboratory-based surveillance uses routine laboratory requisition and testing data to identify and monitor disease activity. The Retro 3 feasibility pilot applied this approach to retrospectively analyze travel-related dengue, Zika, and chikungunya in Canada from 2012 to 2023, now updated through 2024. Results reflect testing conducted at the National Microbiology Laboratory (NML) only, including confirmatory serology for all provinces and territories and molecular testing for all except British Columbia, Alberta, Ontario and Québec, and underestimate the total disease burden.
Chikungunya virus outbreak in Guangdong Province, China (as of August 25, 2025)9,14
As of August 25, 2025, there is a chikungunya virus outbreak in Guangdong Province, China
  • As of September 27, 2025, a total of 16,452 locally transmitted cases have been reported in Guangdong Province.
  • The CDC issued at Level 2 Health Alert Network Health Advisory to warn clinicians, travellers, and public health authorities to practice enhanced precautions.
Chikungunya virus outbreak in Cuba (as of September 26, 2025)16
As of September 26, 2025, there is a chikungunya virus outbreak in Cuba.
  • As of January 3, 2026, a total of 51,217 cases have been reported in Cuba.17
  • The CDC issued at Level 2 Health Alert Network Health Advisory to warn clinicians, travellers, and public health authorities to practice enhanced precautions.
Valneva Canada Inc.
Commercial Operations
3535 Saint-Charles Blvd., Suite 600
Kirkland (Montreal), Quebec H9H 5B9, Canada
Telephone: 514-630-6999